From molecule to vertigo medicine
Its chemical history dates back to 1901. From the 1950s, acetyl-DL-leucine was developed as a drug for vertigo; in France, this use remains part of its pharmaceutical history today.
AFEGA Research Group
Substance profile 04 · N-acetyl-DL-leucine
Acetyl-DL-leucine
A drug substance between vertigo treatment, neurological research and personal hope.
Acetyl-DL-leucine has been used for vertigo for decades. Later, people with ataxias and rare neurological diseases reported very different experiences. Individual observations in REM sleep behaviour disorder and research into the isolated L-form brought renewed attention. This profile tells the story of that development — while consistently keeping substance forms, experiential knowledge and scientific evidence distinct.
A substance with several histories
Four stages shape today’s picture.
Chemical description, drug history, neurological repurposing and enantiomer research are connected — but not interchangeable.
From vertigo to ataxia
The close relationship between vestibular and cerebellar functions led to trials in ataxias. Early open-label case series appeared encouraging, whereas the larger placebo-controlled ALCAT study showed no short-term benefit.
Rare diseases
Reports in Niemann-Pick type C, GM2 gangliosidoses and ataxia-telangiectasia broadened the research field. In parallel, the isolated L-form was developed as a separate drug substance.
Parkinson’s hopes and self-experimentation
Two case reports on REM sleep behaviour disorder, patient stories and mechanistic Parkinson’s models reached self-help, integrative medicine and longevity communities.
The central distinction
DL is a racemate
Acetyl-DL-leucine consists of the D- and L-forms. The body absorbs and processes them differently.
L is a separate active substance
N-acetyl-L-leucine is also called levacetylleucine. Positive registration studies of this form are scientifically relevant, but are not direct evidence of efficacy for the DL-racemate.
Leucine is not acetylleucine
The nutritional function of free L-leucine cannot be transferred to acetyl-DL-leucine. Simply halving or doubling the dose does not establish equivalence either.
Attributed effects
What people associate with acetyl-DL-leucine.
Each card starts with the proposed effect and its origins. The scientific assessment follows separately and considers both positive and negative findings.
01
Vertigo and balance
The proposed effect
Acetyl-DL-leucine is proposed to relieve vertigo attacks, support balance control and facilitate adaptation after vestibular disorders.
Where it comes from
The idea rests on decades of use of the medicine Tanganil, early animal experiments and models of stabilising disturbed vestibular neuronal activity.
Experience and meaning
In forums, some people report less vertigo or greater steadiness when standing, while others report no benefit. Non-response is sometimes explained in terms of diagnosis, duration or individual “receptivity”.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 35 %
A long history of use, open-label observations and mechanistic models; modern controlled efficacy data are limited. View the assessed studies →
What is the current state of research?
The current state of research
The French authorisation documents an acknowledged national medicinal use, but does not replace a modern synthesis of efficacy evidence. A systematic review found no suitable published placebo-controlled RCT for clinical vertigo up to 2018. A small study of experimentally induced motion sickness in 20 healthy men showed no benefit. Mechanistic models are plausible, but this does not establish a reliable general clinical benefit.
02
Ataxia, gait and coordination
The proposed effect
People with cerebellar ataxias associate acetyl-DL-leucine with safer walking, steadier standing, better speech or fine motor skills.
Where it comes from
An early case series involving 13 people reported marked short-term improvements. Clinical contacts and study news subsequently became a practical framework of expectations in self-help forums.
Experience and meaning
Positive, negative and ambivalent courses coexist. Relatives and affected individuals sometimes assessed the same change differently; some discontinued because of the effort involved or symptoms.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 40 %
Early open-label case series with small, heterogeneous groups and substantial risks of bias from expectations and the course of symptoms. View the assessed studies →
What is the current state of research?
The current state of research
ALCAT randomised 108 adults and compared six weeks of acetyl-DL-leucine with placebo in a crossover design. No benefit was found for the primary ataxia endpoint. This negative finding is the strongest direct DL evidence for the setting studied. It does not rule out every possible individual response or every rare form of ataxia, but does not support a general efficacy claim.
03
Rare neurological diseases
The proposed effect
In Niemann-Pick type C, GM2 gangliosidoses and ataxia-telangiectasia, the hope is to stabilise neurological functions or slow deterioration.
Where it comes from
Open-label DL case series, observations on withdrawal, animal models and later the targeted development of the isolated L-form formed a connected research history that nevertheless branched into distinct substance forms.
Experience and meaning
In severe progressive diseases, even small everyday changes can matter greatly. Patient organisations and researchers therefore emphasise careful documentation of individual courses.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 40 %
Small open-label DL case series and preclinical models; different diseases and substance forms are easily conflated. View the assessed studies →
What is the current state of research?
The current state of research
For the DL-racemate, the evidence consists mainly of small open-label case series — interesting signals, but no confirmed disease modification. The situation for N-acetyl-L-leucine is separate: a placebo-controlled NPC RCT showed neurological benefit over twelve weeks; the L-form is authorised for this in the USA and the EU. In ataxia-telangiectasia, a larger positive L-form RCT is also available in 2026, alongside an earlier small negative trial. These L-form results must not be presented as direct DL evidence.
04
REM sleep behaviour disorder and hopes concerning Parkinson’s
The proposed effect
Acetyl-DL-leucine is proposed as potentially delaying the transition from isolated REM sleep behaviour disorder to Parkinson’s or influencing early disease-related processes.
Where it comes from
Two cases followed for a long time, with diary and DAT-SPECT data, were presented in amplified form in professional and supporter communications. Patient stories and integrative medicine sometimes interpreted the imaging as a reversal of degeneration.
Experience and meaning
Quieter nights, hopes of gaining time and observations on stopping and restarting feature in the reports. For people at high risk of disease, this hope understandably carries great weight.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 20 %
Two iRBD observations and a single Parkinson’s case, without randomisation, blinding or a robust prevention endpoint. View the assessed studies →
What is the current state of research?
The current state of research
The case observations are a signal worth investigating, but are not randomised. DAT-SPECT measures transporter binding, not directly the number of preserved neurons. One person developed mild cognitive impairment despite the reported course. Preclinical Parkinson’s work concerns mainly the L-form. Neither Parkinson’s prevention nor neuronal regeneration by the DL-racemate has been demonstrated in humans.
05
Alertness, clarity and cognitive performance
The proposed effect
Acetyl-DL-leucine is associated with greater alertness, clearer thinking, faster reactions and “mental strength”.
Where it comes from
The narrative draws on individual older people, patent examples involving a few healthy adults and self-experiments that sometimes combined many measures at once.
Experience and meaning
Mental presence matters immediately at a subjective level. Sleep, practice, expectations and parallel interventions, however, make attribution to a single substance difficult.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 20 %
Letters on individual cases, patent examples and self-observations with risks of bias from practice, expectations and combinations. View the assessed studies →
What is the current state of research?
The current state of research
The direct human evidence consists of small open-label observations and patent examples; controlled confirmation in healthy people is lacking. Neurological improvements in specific diseases cannot be transferred to normal cognition. A general nootropic effect is therefore not established.
06
Neuroprotection, mitochondria and longevity
The proposed effect
Effects on autophagy, lysosomes, energy and stress processes gave rise to hopes of general neuronal protection and healthy ageing.
Where it comes from
Animal models of rare storage diseases, cell and animal models of brain trauma or Parkinson’s and longevity forums linked disease-specific findings with broader ageing hypotheses.
Experience and meaning
Someone taking a substance long-term as a preventive measure may experience this as actively engaging with ageing. It does not, however, reveal an effect on lifespan or biological ageing.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 30 %
Disease-specific cell and animal models are extrapolated to general neuroprotection and healthy ageing. View the assessed studies →
What is the current state of research?
The current state of research
Several disease-related models show interesting neurobiological and metabolic signals; an L-CLN1 model, however, was negative. Survival benefits in disease models with genetically severely shortened lives are not lifespan extension in healthy organisms. Human studies on healthy lifespan, biological rejuvenation or long-term prevention are lacking.
Personal experience
A clear observation design matters especially when symptoms fluctuate.
The reported experiences range from marked improvement through temporary changes or changes noticed only by relatives to no benefit and symptoms. No success rate can be calculated from these reports.
Record the substance form unambiguously
The DL-racemate, pure L-form and free leucine are often confused in discussions. The name, manufacturer and actual form belong in the observation record.
Define beforehand what should change
Gait, vertigo, sleep, reaction time and subjective clarity are different endpoints. An after-the-fact explanation in terms of responder status can mislead.
Document the course and accompanying measures
Natural fluctuations, rehabilitation, medicines and other self-experiments can contribute to a change. Non-response and unwanted reactions also belong in the overall record.
Substance form, absorption & metabolism
Biologically, the enantiomers do not behave like two equal halves.
A 1:1 mixture at ingestion does not mean that D and L are later present in equal amounts in blood, muscle or brain.
Acetyl-DL-leucine
The racemate contains the D- and L-forms. A complete stereoselective human account of bioavailability, organ distribution and excretion is lacking for oral DL.
N-acetyl-L-leucine
The isolated L-form is preferentially deacetylated and moved by specific transporters. Its authorisation and study data remain distinct.
N-acetyl-D-leucine
In the mouse model, D exposure was markedly higher after administration of the racemate. This establishes neither proven long-term harm nor therapeutic equivalence.
DL, L, D or free leucine?
Which transporters move which form?
How much is deacetylated to leucine and acetate?
Which function actually changes?
The same nominal L amount in N-acetyl-L-leucine and in the DL-racemate does not establish equal exposure or effect. A mathematical dose conversion is not scientifically substantiated.
Studied dosages
Study and medicinal doses are not recommendations for healthy people.
Research uses very different regimens according to substance form, disease and authorisation. There is no robustly justified dose for cognition, prevention or longevity.
French DL prescribing information
Usual medicinal context for vertigo; potentially higher daily amounts and limited duration.
ALCAT
Studied for six weeks after dose escalation — with no benefit over placebo in the primary endpoint.
L-form in NPC
Authorised weight-based doses for a distinct substance form and indication.
Use in healthy people
No established benefit–risk balance and no “anti-ageing dose”.
Safety & interactions
A long history of use does not automatically mean risk-free continuous use.
Safety depends on substance form, dose, duration, disease and concomitant medication. A lack of interaction studies does not mean freedom from interactions.
Direct DL data
Predominantly limited short-term experience — with specific warning signals.
Serious adverse events were documented in ALCAT, although their number alone does not establish causality. The French prescribing information lists very rare skin reactions, abdominal pain and severe hypersensitivity reactions of unknown frequency.
Signals of neurological deterioration
Deterioration and falls were reported in advanced multiple system atrophy; in an RFC1 series, events included vertigo, oedema and subjective memory problems.
Pregnancy and breastfeeding
The French DL prescribing information advises precautionary avoidance during pregnancy and no use while breastfeeding. The L-form has additional reproductive guidance of its own.
Organ function and children
Robust specific DL dosing data are lacking for renal or hepatic impairment. Disease-specific paediatric studies do not establish general safety of use in children.
Combining with the L-form
Regulatory information on the L-form advises against combining it with DL or D. Other potential transporter interactions have not yet been fully clarified.
Regulatory context
Medicinal authorisation, food status and advertising are different questions.
National authorisation for vertigo
The oral DL medicine reviewed is authorised there for symptomatic treatment of vertigo attacks in adults. This does not imply EU-wide authorisation for DL.
NPC authorisation of the L-form
Levacetylleucine is authorised for neurological manifestations of Niemann-Pick type C — not the DL-racemate.
No automatic clearance
A history of medicinal use does not automatically permit marketing as a food supplement or disease-related advertising claims. The product’s legal marketability must be assessed separately.
Frequently asked questions
The key distinctions at a glance.
Many misunderstandings arise from conflating the racemate, the L-form, medicinal tradition, case reports and preclinical research.
01Is acetyl-DL-leucine simply leucine?
No. Acetylation and stereochemistry change the compound. The essential nutritional function of L-leucine does not establish a requirement for acetyl-DL-leucine.
02Are acetyl-DL-leucine and N-acetyl-L-leucine the same?
No. One is a mixture of the D- and L-forms, the other only the L-form. Absorption, metabolism, authorisation and evidence must not be equated.
03Does the DL-racemate help with ataxia?
Some early open-label reports were positive. However, the principal placebo-controlled ALCAT trial showed no short-term benefit in the primary ataxia endpoint.
04Does it prevent Parkinson’s?
This has not been demonstrated. Two cases in REM sleep behaviour disorder and a later single Parkinson’s case are interesting signals, but not a controlled prevention study.
05Can it regenerate neurons?
Preclinical models show potential protective and metabolic effects. Imaging changes in individual cases do not, however, establish regeneration or restoration of lost neurons.
06Does it improve alertness or cognitive performance?
There are individual open-label observations and patent examples, but no robust placebo-controlled confirmation in healthy people.
07Is long-term use safe?
General long-term safety in healthy people is not sufficiently established. Hypersensitivity reactions, disease-specific deterioration signals and limited interaction data must be considered.
08Is there a longevity dose?
No. Study and medicinal doses come from specific disease contexts. Efficacy and long-term safety data for healthy ageing are lacking.
Study-specific claims
How likely is each narrowly defined statement to be true?
Each percentage refers exclusively to the claim written beside it. The assessment is not whether a substance “works overall”, but how plausible the specific statement is in light of the study, counterfindings and applicability.
Two different measures: the small bars in the effect cards assess the strength of two evidence bases. The detailed percentages below instead assess the probability of each specifically formulated claim. Study quality is an important basis for this, but is not equivalent to truth.
Strupp et al. 2013approx. 30 %
Acetyl-DL-leucine improves ataxia symptoms in the short term in people with degenerative ataxia.
Estimated probability that this claim is true: approx. 30 %
Rationale: Positive open-label case series with 13 people; the lack of control and the later negative ALCAT RCT markedly lower the probability of a general effect.
Pelz et al. 2015approx. 40 %
Acetyl-DL-leucine improves clinical signs of ataxia in the short term in Niemann-Pick type C.
Estimated probability that this claim is true: approx. 40 %
Rationale: Small open-label observation in a rare disease; a clinical signal, but without blinding or placebo control.
ALCAT RCT 2021approx. 15 %
In the degenerative and inflammatory ataxias studied in the ALCAT RCT, acetyl-DL-leucine improves the primary ataxia endpoint after six weeks compared with placebo.
Estimated probability that this claim is true: approx. 15 %
Rationale: A randomised placebo-controlled crossover RCT with 108 adults showed no benefit; the strongest direct DL evidence for this setting.
Kaya et al. 2020/2021approx. 35 %
Acetyl-DL-leucine produces clinically relevant disease modification in NPC or GM2 gangliosidosis.
Estimated probability that this claim is true: approx. 35 %
Rationale: Open-label rare-disease data and preclinical signals; small samples and no controlled DL confirmation.
Fields et al. 2024approx. 85 %
N-acetyl-L-leucine improves neurological symptoms over twelve weeks in Niemann-Pick type C.
Estimated probability that this claim is true: approx. 85 %
Rationale: Placebo-controlled RCT with a disease-specific clinical endpoint and regulatory review; applies to the pure L-form, not automatically to the DL-racemate.
Ataxia-telangiectasia RCT 2026approx. 75 %
N-acetyl-L-leucine improves neurological function in ataxia-telangiectasia over the duration studied.
Estimated probability that this claim is true: approx. 75 %
Rationale: Larger positive randomised L-form RCT alongside an earlier small negative trial; disease- and substance-form-specific.
Churchill et al. 2020approx. 90 %
The D- and L-enantiomers of acetylleucine show markedly different pharmacokinetics in mice.
Estimated probability that this claim is true: approx. 90 %
Rationale: Direct enantiomer-specific measurements; human relevance and clinical benefit remain separate.
Churchill et al. 2021approx. 85 %
N-acetyl-L-leucine is processed via specific transport and metabolic pathways in the cell and animal models used.
Estimated probability that this claim is true: approx. 85 %
Rationale: Several mechanistic experiments support the narrow finding; clinical superiority in humans does not follow from it.
Oertel et al. 2024approx. 10 %
Acetyl-DL-leucine prevents the development of Parkinson’s or dementia in people with isolated REM sleep behaviour disorder.
Estimated probability that this claim is true: approx. 10 %
Rationale: Two case observations without control and without sufficient duration to demonstrate prevention; substantial risks in extrapolation and selection.
Single Parkinson’s case 2025approx. 15 %
Acetyl-DL-leucine slows disease progression in Parkinson’s to a clinically relevant degree.
Estimated probability that this claim is true: approx. 15 %
Rationale: Single case with imaging and clinical observation; spontaneous course, concomitant treatment and measurement variation are not controlled.
Song et al. 2026approx. 85 %
N-acetyl-L-leucine protects dopaminergic systems in the Parkinson’s cell and animal models studied.
Estimated probability that this claim is true: approx. 85 %
Rationale: Several consistent preclinical experiments; transferability to clinical benefit in humans remains low.
MSA case series 2025approx. 35 %
Acetyl-DL-leucine can worsen symptoms in multiple system atrophy.
Estimated probability that this claim is true: approx. 35 %
Rationale: Small, uncontrolled safety signal; to be taken seriously, but frequency and causality remain uncertain.
Vibert & Vidal 2001approx. 85 %
Acetyl-DL-leucine alters vestibular neuronal activity in the vestibular animal model used.
Estimated probability that this claim is true: approx. 85 %
Rationale: Direct mechanistic model finding; it establishes neither general neurological benefit nor longevity in humans.
Fields et al. 2024 — extrapolation to the racemateCannot be reliably quantified
The benefit observed with N-acetyl-L-leucine in NPC is transferable at the same magnitude to acetyl-DL-leucine.
Estimated probability that this claim is true: cannot be reliably quantified
Rationale: The pure L-form and DL-racemate differ in substance form and pharmacokinetics; a direct comparison with the same population and endpoint is lacking.
Important: “not independently supported” does not mean “disproved”. Conversely, a lack of disproof is not evidence of efficacy. Substance form, dose, population, duration and endpoint limit every statement.
Sources & transparency
The origin of a hope and evidence of an effect remain distinct.
This profile considers the long medicinal history, positive, negative and ambivalent experiences, controlled studies, case reports, preclinical models and regulatory information. Multiple texts about the same people or studies are not counted as independent confirmations.
Transparency note
The AFEGA Anti-Aging-Shop, operated separately from the AFEGA Research Group, offers acetyl-DL-leucine. The scientific assessment is made independently of product interests. This profile is neither a product evaluation nor a recommendation for use.
- 01Feil et al. 2021: ALCAT RCT ↗
- 02Strupp et al. 2013: ataxia case series ↗
- 03Kaya et al. 2020/2021: NPC and GM2 ↗
- 04Fields et al. 2024: N-acetyl-L-leucine in NPC ↗
- 05Oertel et al. 2024: iRBD case observations ↗
- 06MSA: negative safety signal 2025 ↗
- 07Churchill et al. 2020: enantiomer pharmacokinetics ↗
- 08Churchill et al. 2021: transport and metabolism ↗
- 09Vibert & Vidal 2001: vestibular mechanisms ↗
- 10Song et al. 2026: Parkinson’s models of the L-form ↗
- 11France: Tanganil prescribing information ↗
- 12FDA: levacetylleucine prescribing information ↗
- 13EMA: Aqneursa/levacetylleucine ↗
AFEGA’s perspective
Acetyl-DL-leucine is scientifically interesting because decades of medicinal experience, very different personal observations and modern neurological research meet. There are signals worth investigating in individual diseases; robust confirmation of a general neurological, cognitive or longevity benefit of the DL-racemate is still lacking.Go to the substance library →